142893-46-7

Basic information

• Product Name: 5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carbonitrile
• Synonyms: 5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carbonitrile
• CAS NO: 142893-46-7
• Molecular Formula: C₁₁H₁₀N₄
• Molecular Weight: 198.2239
• Mol File: 142893-46-7.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carbonitrile(142893-46-7)
• EPA Substance Registry System: 5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carbonitrile(142893-46-7)

Safety Data

• Hazardous Substances Data: 142893-46-7(Hazardous Substances Data)

Upstream product

• 635-26-7 o-tolylhydrazine hydrochloride 
• 123-06-8 Ethoxymethylenemalononitrile 
• 86240-43-9 (ethoxymethylene)malononitrile 
• 529-27-1 2-methylphenylhydrazine 

Downstream Products

• 792953-11-8 (5-amino-1-o-tolyl-1H-pyrazole-4-carboxamide) 
• 733737-73-0 (1-o-tolyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-hydrazine 
• 650628-61-8 4-chloro-1-(2-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidine 
• 919217-49-5 1-o-tolyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one 

Relevant articles and documents

COMBINATION THERAPY FOR TREATING MPS1

The application is directed to compounds of formula (I) and their salts and solvates, wherein B, R1, R2, R3, R3', R4, R4', and R5 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., MPS1, optionally in combination with α-L-iduronidase or an analog or variant thereof, e.g., laronidase.

Discovery and evaluation of 7- lkyl-1,5-bis-aryl-pyrazolopyridinones as Highly potent, selective, and orally efficacious inhibitors of p38α mitogen-activated protein kinase

The p38α mitogen-activated protein (MAP) kinase is a central signaling molecule in many proinflammatory pathways, regulating the cellular response to a multitude of external stimuli including heat, ultraviolet radiation, osmotic shock, and a variety of cytokines especially interleukin-1- and tumor necrosis factor α. Thus, inhibitors of this enzyme are postulated to have significant therapeutic potential for the treatment of rheumatoid arthritis, inflammatory bowel disease, and Crohn's disease, as well as other diseases where aberrant cytokine signaling is the driver of disease. In this communication, we describe a novel class of 7-alkyl-1,5-bis-aryl- pyrazolopyridinone-based p38α inhibitors. In particular, compound 3f is highly potent in the enzyme and cell-based assays, selective in an Ambit kinase screen, and efficacious (ED50 - 0.01 mg/kg) in the rat collagen induced arthritis (CIA) model.

6-ARYLMETHYL-SUBSTITUTED PYRAZOLOPYRIMIDINES

The invention relates to novel 6-arylmethyl-substituted pyrazolopyrimidines of formula (I) wherein R1 represents phenyl, pyridyl or thiophenyl, and R2 represents phenyl or heteroaryl. The invention also relates to the salts and solvates thereof, and/or solvates of the salts thereof, to methods for producing said pyrazolopyrimidines, and to the use of the same for producing pharmaceuticals for improving perception, power of concentration, learning capacity and/or memory retention.